Biological Effect of Human Serum Collected Before and After Oral Intake of Pygeum Africanum on Various Benign Prostate Cell Cultures

Overview

Journal Asian J Androl

Specialty Urology

Date 2011 Dec 27

PMID 22198631

Citations 4

Authors

Stephane Larre

Philippe Camparo

Eva Comperat

Delphine Boulbes

Mohammed Haddoum

Sylvain Baulande

Pascal Soularue

Pierre Costa

Olivier Cussenot

Affiliations

Soon will be listed here.

Abstract

Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia. The active compounds of the drug have not been identified, and determining the plasma concentration of the drug is, therefore, not possible. Because there are conflicting results on the efficacy of this drug, we aimed to investigate its effect on prostate cell growth in vitro using human serum collected before and after Pygeum africanum intake. We used primary and organotypic cultures of human prostatic stromal myofibroblast cell line WPMY and prostatic epithelial cell line PNT2. We also used fresh benign prostatic tissue. The serum of a treated man induced decreases in the proliferation of primary cells, organotypic cells and WPMY cells but not PNT2 cells. We also analysed the effect of treated serum on the gene expression profile of WPMY cells. The transcriptome analysis revealed an upregulation of genes involved in multiple tumour suppression pathways and a downregulation of genes involved in inflammation and oxidative-stress pathways. The oral intake of Pygeum africanum resulted in serum levels of active substances that were sufficient to inhibit the proliferation of cultured myofibroblasts prostatic cells. This inhibition was associated with changes in the transcriptome.

Citing Articles

Treatment of Benign Prostatic Hyperplasia by Natural Drugs.

Csikos E, Horvath A, Acs K, Papp N, Balazs V, Dolenc M Molecules. 2021; 26(23).

PMID: 34885733 PMC: 8659259. DOI: 10.3390/molecules26237141.

Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH).

Paterniti I, Campolo M, Cordaro M, Siracusa R, Filippone A, Esposito E Inflamm Res. 2018; 67(7):617-626.

PMID: 29679313 DOI: 10.1007/s00011-018-1152-9.

Ethanol Extract of Root of Inhibited the Growth of Liver Cancer Cell HepG2 by Inducing Cell Cycle Arrest and Migration Suppression.

Shen H, Wang H, Wang L, Wang L, Zhu M, Ming Y Evid Based Complement Alternat Med. 2017; 2017:8231936.

PMID: 29234432 PMC: 5660787. DOI: 10.1155/2017/8231936.

Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C Br J Pharmacol. 2012; 167(1):95-108.

PMID: 22471974 PMC: 3448916. DOI: 10.1111/j.1476-5381.2012.01969.x.

References

Buck A . Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004; 172(5 Pt 1):1792-9. DOI: 10.1097/01.ju.0000140503.11467.8e. View

Boulbes D, Soustelle L, Costa P, Haddoum M, Bali J, Hollande F . Pygeum africanum extract inhibits proliferation of human cultured prostatic fibroblasts and myofibroblasts. BJU Int. 2006; 98(5):1106-13. DOI: 10.1111/j.1464-410X.2006.06483.x. View

Takikawa M, Akiyama Y, Maruyama K, Suzuki A, Liu F, Tai S . Proteomic analysis of a highly metastatic gastric cancer cell line using two-dimensional differential gel electrophoresis. Oncol Rep. 2006; 16(4):705-11. View

Madersbacher S, Alivizatos G, Nordling J, Rioja Sanz C, Emberton M, de la Rosette J . EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004; 46(5):547-54. DOI: 10.1016/j.eururo.2004.07.016. View

Cui H, Darmanin S, Natsuisaka M, Kondo T, Asaka M, Shindoh M . Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. Cancer Res. 2007; 67(7):3345-55. DOI: 10.1158/0008-5472.CAN-06-2519. View

Shenouda N, Sakla M, Newton L, Besch-Williford C, Greenberg N, MacDonald R . Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007; 31(1):72-81. DOI: 10.1007/s12020-007-0014-y. View

Abraham R . The ATM-related kinase, hSMG-1, bridges genome and RNA surveillance pathways. DNA Repair (Amst). 2004; 3(8-9):919-25. DOI: 10.1016/j.dnarep.2004.04.003. View

Ishani A, MacDonald R, Nelson D, Rutks I, Wilt T . Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med. 2000; 109(8):654-64. DOI: 10.1016/s0002-9343(00)00604-5. View

Yablonsky F, Nicolas V, Riffaud J, Bellamy F . Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol. 1997; 157(6):2381-7. View

10.

Quiles M, Arbos M, Fraga A, de Torres I, Reventos J, Morote J . Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Prostate. 2010; 70(10):1044-53. DOI: 10.1002/pros.21138. View

11.

Descazeaud A, Rubin M, Hofer M, Setlur S, Nikolaief N, Vacherot F . BPH gene expression profile associated to prostate gland volume. Diagn Mol Pathol. 2008; 17(4):207-13. PMC: 2822796. DOI: 10.1097/PDM.0b013e31816f6352. View

12.

Levin R, Das A . A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res. 2000; 28(3):201-9. DOI: 10.1007/s002409900098. View

13.

Shintani M, Tada M, Kobayashi T, Kajiho H, Kontani K, Katada T . Characterization of Rab45/RASEF containing EF-hand domain and a coiled-coil motif as a self-associating GTPase. Biochem Biophys Res Commun. 2007; 357(3):661-7. DOI: 10.1016/j.bbrc.2007.03.206. View

14.

Papini S, Rosellini A, De Matteis A, Campani D, Selli C, Caporali A . Establishment of an organotypic in vitro culture system and its relevance to the characterization of human prostate epithelial cancer cells and their stromal interactions. Pathol Res Pract. 2007; 203(4):209-16. DOI: 10.1016/j.prp.2007.02.004. View

15.

Verlaan D, Davenport W, Stefan H, Sure U, Siegel A, Rouleau G . Cerebral cavernous malformations: mutations in Krit1. Neurology. 2002; 58(6):853-7. DOI: 10.1212/wnl.58.6.853. View

16.

Kassen A, Berges R, Senge T . Effect of beta-sitosterol on transforming growth factor-beta-1 expression and translocation protein kinase C alpha in human prostate stromal cells in vitro. Eur Urol. 2000; 37(6):735-41. DOI: 10.1159/000020227. View

17.

Muller-Tidow C, Diederichs S, Thomas M, Serve H . Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. Lung Cancer. 2004; 45 Suppl 2:S145-50. DOI: 10.1016/j.lungcan.2004.07.979. View

18.

Postigo A . Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway. EMBO J. 2003; 22(10):2443-52. PMC: 155983. DOI: 10.1093/emboj/cdg225. View

19.

Ropiquet F, Berthon P, Villette J, Le Brun G, Maitland N, Cussenot O . Constitutive expression of FGF2/bFGF in non-tumorigenic human prostatic epithelial cells results in the acquisition of a partial neoplastic phenotype. Int J Cancer. 1997; 72(3):543-7. DOI: 10.1002/(sici)1097-0215(19970729)72:3<543::aid-ijc26>3.0.co;2-b. View

20.

Iida R, Yasuda T, Tsubota E, Takatsuka H, Matsuki T, Kishi K . Human Mpv17-like protein is localized in peroxisomes and regulates expression of antioxidant enzymes. Biochem Biophys Res Commun. 2006; 344(3):948-54. DOI: 10.1016/j.bbrc.2006.04.008. View